Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment. READ MORE
The US Food and Drug Administration has approved the second CAR T-cell therapy, indicated for certain types of non-Hodgkin lymphoma.
The US Food and Drug Administration (FDA) has made the first gene therapy available, marking their approval of a new approach to the treatment of cancer.
A recent study reported an ORR of 71% in patients with CLL treated with anti-CD19 CAR-T cell therapy after prior treatment failure.